What Dizal Pharma does

Dizal Pharmaceutical is a Shanghai-based clinical-stage biopharmaceutical company founded in 2017 that develops targeted small-molecule oncology therapies, with primary focus on EGFR tyrosine kinase inhibitors (TKIs) and JAK1-selective inhibitors for non-small cell lung cancer (NSCLC) and hematologic malignancies. The company's flagship asset, ZEGFROVY (sunvozertinib), is an oral, once-daily EGFR TKI designed to target exon 20 insertion mutations, PACC mutations, and other uncommon EGFR alterations; it received FDA accelerated approval in July 2025 for post-platinum EGFR exon20ins NSCLC and was commercially launched in China the same month, making it the only FDA-approved oral targeted therapy for this molecular subtype in the US. The pipeline also includes DZD6008, a fourth-generation EGFR TKI demonstrating 82.1% tumor shrinkage in patients with C797X resistance mutations who relapsed after third-generation TKI therapy; golidocitinib, a JAK1-selective inhibitor approved by China's NMPA for relapsed or refractory peripheral T-cell lymphoma and being evaluated in combination with anti-PD-1 therapy for advanced NSCLC; and birelentinib, a hematology candidate with FDA Fast Track Designation.

The company generates revenue through pharmaceutical drug sales (ZEGFROVY in US and China post-July 2025 launches, golidocitinib in China post-March 2026) and participates in cross-border licensing arrangements. Go-to-market is built on oncology-focused sales teams targeting major cancer treatment centers and thoracic oncology specialists, supported by a companion diagnostic partnership with Thermo Fisher Scientific's Oncomine Dx Express Test in the US for patient identification. Publicly listed on the Shanghai Stock Exchange (SSE:688192), Dizal raised approximately $246 million in April 2025 from Chinese institutional investors (Bosera, Harvest, GF, Fullgoal, Nuode, Penghua, Rosefinch, Taikang) following a prior $100 million round in 2020 led by Lilly Asia Ventures. The company employs 501-1,000 staff and is led by founder and CEO Xiaolin Zhang, with Hongbin Lyu serving as CFO.

Name

Dizal Pharma

Legal name

Dizal Pharmaceutical

Website

http://www.dizalpharma.com/

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Dizal Pharma is a Shanghai-based clinical-stage biopharmaceutical company developing targeted small-molecule oncology therapies, including the FDA-approved EGFR TKI ZEGFROVY (sunvozertinib) for exon 20 insertion-mutated NSCLC, plus a pipeline of next-generation EGFR inhibitors and JAK1 inhibitors for hematologic malignancies.

Ownership category

akta.pro rank

Product category

Targeted Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Targeted oncology therapeutics
• EGFR tyrosine kinase inhibitors
• Lung cancer treatment
• Hematologic malignancy drugs
• Precision oncology pharmaceuticals

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Pharmaceutical Drug Sales: Dizal Pharma generates revenue through the sale of its approved and pipeline oncology drugs. ZEGFROVY (sunvozertinib) received FDA accelerated approval in July 2025 for EGFR exon 20 insertion mutation-positive NSCLC patients who have progressed after platinum-based chemotherapy, and was launched commercially in China in July 2025. The company is pursuing additional approvals globally, with potential for significant revenue from first-line NSCLC treatment if ZEGFROVY receives expanded approval.
2. Licensing and Strategic Partnerships: Dizal participates in cross-border licensing deals, with upfront values in the Chinese biotech sector increasing significantly ($1.1 billion in 2022 to $5.6 billion in 2025), indicating Dizal is both a licensor of its drug candidates and a party to strategic co-development partnerships with global pharmaceutical companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Dizal Pharma develops and commercializes targeted small-molecule oncology therapies, primarily EGFR tyrosine kinase inhibitors and JAK1-selective inhibitors, for the treatment of non-small cell lung cancer and hematologic malignancies. Its lead asset ZEGFROVY (sunvozertinib) is the only FDA-approved oral targeted therapy for EGFR exon 20 insertion mutation-positive NSCLC, with additional pipeline assets DZD6008, golidocitinib, and birelentinib addressing resistance mutations, peripheral T-cell lymphoma, and other hematologic cancers.

Product overview

Dizal Pharma is a biopharmaceutical company developing targeted oncology therapies, primarily focused on non-small cell lung cancer (NSCLC) treatments. The company's portfolio centers on EGFR tyrosine kinase inhibitors including ZEGFROVY (sunvozertinib), an approved oral targeted therapy for EGFR exon 20 insertion mutations, and DZD6008, a next-generation EGFR TKI in development. Beyond EGFR-targeted therapies, Dizal is expanding into hematology with golidocitinib (approved in China for peripheral T-cell lymphoma) and birelentinib, both showing promise in lymphoma treatments. The company is also exploring combination therapies pairing its JAK1 inhibitor with immunotherapy agents.

Differentiator

Problem solved

Functional benefit

Products and services

• ZEGFROVY (sunvozertinib) Oral, once-daily EGFR tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion mutations, PACC mutations, and other uncommon EGFR mutations in NSCLC. FDA-approved for previously treated patients and under review for first-line treatment. Indicated for adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations after platinum-based chemotherapy progression.
• DZD6008 Fourth-generation EGFR tyrosine kinase inhibitor in clinical development, demonstrating 82.1% tumor shrinkage rate and favorable blood-brain barrier penetration in NSCLC patients with EGFR C797X resistance mutations who relapsed after third-generation EGFR TKI treatment. Targets NSCLC patients with resistance mutations where no approved targeted options exist.
• Golidocitinib JAK1-selective inhibitor approved by China's NMPA for relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). Under Priority Review by China's CDE for PTCL and being evaluated in combination with anti-PD-1 therapy for advanced NSCLC without driver mutations. Indicated for adult patients with r/r PTCL with limited effective treatment options.
• Birelentinib Hematology drug candidate being developed for lymphoma-related conditions, with promising response rates and manageable safety profile presented at ASH 2025. Has received FDA Fast Track Designation, enabling more frequent FDA interactions and rolling review for hematologic malignancy indications with unmet medical need.

Quantifiable outcome

• ZEGFROVY achieved median PFS of 10.3 months vs 7.5 months for platinum-doublet chemotherapy (HR=0.65, p=0.0008) in first-line EGFR exon20ins NSCLC in the WU-KONG28 Phase 3 trial
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

One partnership is on record.

• Thermo Fisher ScientificcoreStrategic or Co-development Partner · 7 July 2025Thermo Fisher Scientific's Oncomine Dx Express Test was simultaneously FDA-approved as a companion diagnostic with ZEGFROVY (sunvozertinib), enabling identification of NSCLC patients with EGFR exon 20 insertion mutations eligible for treatment with Dizal's drug.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ArriVent Biopharma: ArriVent is developing firmonertinib for EGFR-mutant NSCLC, including exon 20 insertion mutations. Directly competes with Dizal's ZEGFROVY in the same indication with similar oral TKI mechanism and is among the closest head-to-head competitors.
• Cullinan Oncology: Cullinan (partnering with Taiho Oncology) developed zipalertinib, an EGFR exon 20 insertion TKI directly competing with ZEGFROVY. Targets the same patient population with a similar oral small-molecule approach.
• Summit Therapeutics: Summit's ivonescimab (PD-1/VEGF bispecific) is being developed for NSCLC and competes for the broader lung cancer market. Listed as a direct EGFR/NSCLC competitor in Dizal's market context with significant China-originated technology.
• HUTCHMED (China): HUTCHMED is a Hong Kong/China-listed biopharma with multiple oncology drugs including surufatinib and fruquintinib. Comparable as a Chinese-headquartered oncology biotech with both domestic and global regulatory presence, similar dual-market strategy to Dizal.

Emerging players

• Black Diamond Therapeutics: Black Diamond focuses on allosteric EGFR inhibitors targeting resistance mutations (including C797X). Shares Dizal's DZD6008 thesis of addressing post-osimertinib resistance and uncommon EGFR mutations through next-generation TKIs.
• Akeso: Akeso is a Chinese biotech with a strong pipeline of bispecific antibodies for oncology including lung cancer (e.g., ivonescimab licensed to Summit). Represents a comparable Chinese biopharma with global out-licensing strategy and similar ASCO 2026-era validation.

Broad incumbents

• BeiGene: BeiGene is the largest Chinese oncology biotech with global commercial reach (zanubrutinib, tislelizumab). Comparable as a Chinese biopharma with FDA approvals, US commercialization infrastructure, and substantial hematology and solid tumor portfolios.
• Innovent Biologics: Innovent is a leading Chinese biopharma with multiple approved biologics (sintilimab) and a broad oncology pipeline including NSCLC programs. Partnered with Dizal (sintilimab + golidocitinib combination) and represents a strategic peer in the Chinese oncology ecosystem.
• Johnson & Johnson (Innovative Medicine): J&J's RYBREVANT (amivantamab) plus lazertinib combination directly competes with ZEGFROVY in EGFR-mutant NSCLC. J&J represents the largest commercial competitive threat with established US oncology salesforce and resources.
• Mirati Therapeutics: Mirati (acquired by Bristol-Myers Squibb) developed targeted oncology therapies including KRAZATI (adagrasib) for KRAS-mutant NSCLC. Comparable as a targeted oncology company with both solid tumor focus and similar precision medicine approach to Dizal.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dizal Pharma